학술논문
The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis
Document Type
Original Paper
Author
Ye, Lan; Greten, Stephan; Wegner, Florian; Doll-Lee, Johanna; Krey, Lea; Heine, Johanne; Gandor, Florin; Vogel, Annemarie; Berger, Luise; Gruber, Doreen; Levin, Johannes; Katzdobler, Sabrina; Peters, Oliver; Dashti, Eman; Priller, Josef; Spruth, Eike Jakob; Kühn, Andrea A.; Krause, Patricia; Spottke, Annika; Schneider, Anja; Beyle, Aline; Kimmich, Okka; Donix, Markus; Haussmann, Robert; Brandt, Moritz; Dinter, Elisabeth; Wiltfang, Jens; Schott, Björn H.; Zerr, Inga; Bähr, Mathias; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Weidinger, Endy; Düzel, Emrah; Glanz, Wenzel; Teipel, Stefan; Kilimann, Ingo; Wurster, Isabel; Brockmann, Kathrin; Hoffmann, Daniel C.; Klockgether, Thomas; Krause, Olaf; Heck, Johannes; Höglinger, Günter U.; Klietz, Martin
Source
Journal of Neurology. 271(5):2639-2648
Subject
Language
English
ISSN
0340-5354
1432-1459
1432-1459
Abstract
Background: Multiple system atrophy (MSA) is a complex and fatal neurodegenerative movement disorder. Understanding the comorbidities and drug therapy is crucial for MSA patients’ safety and management.Objectives: To investigate the pattern of comorbidities and aspects of drug therapy in MSA patients.Methods: Cross-sectional data of MSA patients according to Gilman et al. (2008) diagnostic criteria and control patients without neurodegenerative diseases (non-ND) were collected from German, multicenter cohorts. The prevalence of comorbidities according to WHO ICD-10 classification and drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were identified using AiDKlinik®.Results: The analysis included 254 MSA and 363 age- and sex-matched non-ND control patients. MSA patients exhibited a significantly higher burden of comorbidities, in particular diseases of the genitourinary system. Also, more medications were prescribed MSA patients, resulting in a higher prevalence of polypharmacy. Importantly, the risk of potential drug-drug interactions, including severe interactions and contraindicated combinations, was elevated in MSA patients. When comparing MSA-P and MSA-C subtypes, MSA-P patients suffered more frequently from diseases of the genitourinary system and diseases of the musculoskeletal system and connective tissue.Conclusions: MSA patients face a substantial burden of comorbidities, notably in the genitourinary system. This, coupled with increased polypharmacy and potential drug interactions, highlights the complexity of managing MSA patients. Clinicians should carefully consider these factors when devising treatment strategies for MSA patients.